Form 4: OrbiMed Sells Sionna Therapeutics Shares Under 10b5-1 Plan

OrbiMed Advisors LLC, a significant shareholder and director of Sionna Therapeutics, Inc., reported the sale of 33,356 shares of common stock at $44.55 per share.

Summary

• OrbiMed Advisors LLC, identified as a 10% owner and having a director on the board of Sionna Therapeutics, Inc., reported a transaction.
• A total of 33,356 shares of Sionna Therapeutics, Inc. common stock were disposed of.
• The transaction occurred on December 24, 2025, at a price of $44.55 per share.
• Following this sale, OrbiMed Advisors LLC (indirectly through OrbiMed Private Investments VIII, LP) beneficially owns 3,561,655 shares of common stock.
• The reported transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 4

Explanation: The sale of shares by a significant institutional investor and director, even under a 10b5-1 plan, can be perceived as a slight negative signal by the market, though the pre-scheduled nature mitigates immediate concerns about insider sentiment.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled sale rather than an immediate reaction to new information, which can reduce concerns about insider sentiment.

Negatives

• A significant institutional shareholder and director entity, OrbiMed Advisors LLC, disposed of 33,356 shares of common stock, which can sometimes be perceived negatively by the market.

Future Outlook

This Form 4 filing does not provide any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein, if any.
• The reporting persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors.

Industry Context

This insider transaction report is specific to Sionna Therapeutics, Inc. and its major shareholder, OrbiMed Advisors LLC, and does not provide broader industry trend analysis.

Related Party Transactions

• OrbiMed Advisors LLC, a 10% owner and entity with a director on the board, sold 33,356 shares of Sionna Therapeutics, Inc. common stock.

Stakeholder Impact

• Shareholders may interpret the sale by a significant institutional investor as a signal, potentially influencing market sentiment and share price.

Key Dates

Recommendation

The sale by a significant shareholder, OrbiMed Advisors LLC, of 33,356 shares of Sionna Therapeutics common stock, while notable, appears to be executed under a pre-arranged Rule 10b5-1(c) plan. Such plans are often established in advance to allow insiders to sell shares systematically without being accused of trading on material non-public information. Therefore, this specific transaction, in isolation, does not necessarily signal a change in the fundamental outlook for the company but rather a planned liquidity event for the reporting entity. Investors should monitor future filings and broader company performance for more comprehensive insights before making significant investment decisions.

Keywords

Sionna Therapeutics, SION, OrbiMed Advisors, insider trading, Form 4, stock sale, beneficial ownership, 10b5-1 plan